Stocks · News reference
On October 13, 2026 (the "Effective Date"), DataMeds AI, Inc. ("DataMeds" or the "Company") entered into an Intellectual Property License and Product and Services Agreement (the "IP License
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-16 AccNo: 0001493152-26-047451 Size: 213 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.02: Unregistered Sales of Equity Securities
DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its
Humana includes DataMeds AI's Helomics ChemoFx assay in its Medicaid policy for gynecologic cancers, expanding payer reimbursement.